Tilray Medical Announces Availability Of Medical Cannabis Edibles, Good Supply Pastilles, To Patients In Australia

SYDNEY, April 17, 2025 (GLOBE NEWSWIRE) — Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical’s first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.

Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, stated, “Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences. The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone for Tilray Medical. We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide.”

Good Supply Pastilles are available in the following options:

• Good Supply Pastilles THC10 (Strawberry)
• Good Supply Pastilles THC10 CBD10 (Pineapple)
• Good Supply Pastilles CBD20 (Raspberry)

   

Medical cannabis patients are now able to purchase the Good Supply Pastilles in packs of 60 from Tilray Direct or their local medical cannabis distributors.

Tilray continues to be a leading provider of EU-GMP certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers globally. Today, Tilray offers a comprehensive portfolio of THC and CBD products in over 20 countries, supporting medical trials worldwide to study the efficacy of medical cannabis for various conditions.